Free Trial

Cidara Therapeutics Q4 2024 Earnings Report

Cidara Therapeutics logo
$21.92 -0.47 (-2.10%)
As of 12:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cidara Therapeutics EPS Results

Actual EPS
-$5.38
Consensus EPS
-$5.28
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Cidara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cidara Therapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Cidara Therapeutics Earnings Headlines

7 Stocks Set to Win Big Under Trump’s America First Agenda 🚀
The Trump economy is back in full force, and it’s creating huge opportunities for investors. With Trump pushing for lower taxes, fewer regulations, tariffs on foreign competitors, and domestic manufacturing dominance, some stocks are set to skyrocket in value—while others will be left behind. That’s why we put together this free report revealing the 7 MAGA stocks poised to thrive in 2025.
Cidara Therapeutics to present on CD388 at ICAR 2025
See More Cidara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cidara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cidara Therapeutics and other key companies, straight to your email.

About Cidara Therapeutics

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

View Cidara Therapeutics Profile

More Earnings Resources from MarketBeat